Cargando…

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies

BACKGROUND: The role of re-immunotherapy in advanced non-small cell lung cancer (NSCLC) remains unclear. No studies have evaluated the re-immunotherapy regimen including anti-cytotoxic T-lymphocyte antigen-4 antibody for lung cancer treatment. This study aimed to investigate the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imakita, Takuma, Fujita, Kohei, Ito, Takanori, Saito, Zentaro, Oi, Issei, Kanai, Osamu, Tachibana, Hiromasa, Sawai, Satoru, Mio, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471535/ https://www.ncbi.nlm.nih.gov/pubmed/37653078 http://dx.doi.org/10.1007/s12672-023-00781-5

Ejemplares similares

Safety and Efficacy of Flexible Bronchoscopy in Elderly Patients: A Retrospective Comparative Study
por: Saito, Zentaro, et al.
Publicado: (2023)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Pegfilgrastim-Induced Aortitis in a Patient with Small-Cell Lung Cancer Who Received Immunotherapy Combined with Chemotherapy
por: Ito, Takanori, et al.
Publicado: (2023)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

A 92‐year‐old patient with thoracic empyema successfully treated by CT‐guided insertion of a pigtail catheter
por: Fujita, Kohei, et al.
Publicado: (2023)

Simultaneous regression of non‐small cell lung cancer and orbital extranodal marginal zone lymphoma with chemoradiotherapy for lung cancer
por: Oi, Issei, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on the trajectory of the number of bronchoscopies performed in a tertiary hospital in Kyoto city
por: Fujita, Kohei, et al.
Publicado: (2023)

Comparison of frailty in patients with nontuberculous mycobacterial lung disease and bronchiectasis: a prospective cohort study
por: Fujita, Kohei, et al.
Publicado: (2022)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
por: Imakita, Takuma, et al.
Publicado: (2017)

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab
por: Parker, Matthew JS, et al.
Publicado: (2018)

Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor
por: Shimatani, Kimihiro, et al.
Publicado: (2018)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019)

Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study
por: Chen, Yaolin, et al.
Publicado: (2021)

Concomitant Anti-GBM Glomerulonephritis and Acute Interstitial Nephritis Following Programmed Death Receptor-1 Blockade With Nivolumab
por: Tani, Takashi, et al.
Publicado: (2022)

Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab
por: Baxi, Vipul, et al.
Publicado: (2022)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
por: Ascierto, Paolo Antonio, et al.
Publicado: (2023)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Imakita, Takuma, et al.
Publicado: (2021)

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature
por: TSIOGKA, Aikaterini, et al.
Publicado: (2021)

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report
por: Fuu, Takayoshi, et al.
Publicado: (2022)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
por: Liu, Gang, et al.
Publicado: (2021)

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
por: Ready, Neal, et al.
Publicado: (2019)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Anti-Programmed Cell Death-1-Induced Plaque and Guttate Psoriasis
por: Yamamoto, Toshiyuki
Publicado: (2018)

Sick sinus syndrome associated with anti-programmed cell death-1
por: Hsu, Chien-Yi, et al.
Publicado: (2018)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Natural course of pulmonary hyalinizing granuloma over a decade
por: Fujita, Kohei, et al.
Publicado: (2022)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
por: Imakita, Takuma, et al.
Publicado: (2022)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
por: Gill, Amanda L., et al.
Publicado: (2016)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
por: Shen, John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n0ackugmi1lqmsssmjimfbur34